Two novel TSC2 mutations in pediatric patients with tuberous sclerosis complex

Rationale: Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder. The TSC1 and TSC2 genes have been identified as pathogenic genes. Patient concerns: In this report, we are discussing a novel frameshift mutation and a novel missense mutation in the TSC2 gene. Diagnoses: The two cases discussed in this study met the latest diagnostic criteria for TSC published by the International Tuberculosis Sclerosis Complex Consensus Conference in 2012. Interventions: High-throughput sequencing and multiplex ligation-dependent probe amplification (MLPA) were used to examine tuberous sclerosis complex (TSC)-related genes (TSC1 and TSC2) and their splicing regions using peripheral blood DNA from two probands in two families with TSC and to identify the genetic mutation sites. Amplification primers were designed for the mutation sites, and polymerase chain reaction and Sanger sequencing were used to verify the peripheral blood DNA sequences from the probands and their parents. Outcome: Proband 1 had the c.1228 (exon 12)_c.1229 (exon 12) insG (p.L410RfsX11) heterozygous mutation in the TSC2 gene (chr16), which was a new frameshift mutation. Proband 2 had the c.4925G>A (exon 38) (p.G1642D) heterozygous mutation in the TSC2 gene (chr16), which was a new missense mutation. Lessons: These two novel mutations may be pathogenic mutations for TSC, and their association with the disease needs to be further verified by mutant protein function cell model and animal model.

[1]  Chia-Hao Liu,et al.  Malignant perivascular epithelioid cell tumor in the female genital tract , 2019, Medicine.

[2]  Weiqin Wu,et al.  [Two novel TSC2 frameshift mutations in tuberous sclerosis complex]. , 2017, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics.

[3]  S. Peng,et al.  The relationship of neuroimaging findings and neuropsychiatric comorbidities in children with tuberous sclerosis complex. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[4]  E. Roach,et al.  Tuberous sclerosis complex. , 2015, Handbook of clinical neurology.

[5]  L. Lagae,et al.  Tuberous sclerosis complex: the past and the future , 2015, Pediatric Nephrology.

[6]  T. H. Sasongko,et al.  Two novel gross deletions of TSC2 in Malaysian patients with tuberous sclerosis complex and TSC2/PKD1 contiguous deletion syndrome. , 2014, Japanese journal of clinical oncology.

[7]  M. Ikura,et al.  Structure-guided Mutation of the Conserved G3-box Glycine in Rheb Generates a Constitutively Activated Regulator of Mammalian Target of Rapamycin (mTOR)* , 2014, The Journal of Biological Chemistry.

[8]  D. Krueger,et al.  Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.

[9]  O. Devinsky,et al.  MRI Characterization and Longitudinal Study of Focal Cerebellar Lesions in a Young Tuberous Sclerosis Cohort , 2013, American Journal of Neuroradiology.

[10]  P. Crino Evolving neurobiology of tuberous sclerosis complex , 2013, Acta Neuropathologica.

[11]  B. Taillon,et al.  Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex , 2010, Human Genetics.

[12]  P. V. van Rijen,et al.  Gene Expression Analysis of Tuberous Sclerosis Complex Cortical Tubers Reveals Increased Expression of Adhesion and Inflammatory Factors , 2009, Brain pathology.

[13]  V. Napolioni,et al.  Recent advances in neurobiology of Tuberous Sclerosis Complex , 2009, Brain and Development.

[14]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[15]  M. Goedbloed,et al.  Characterisation of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis , 2004, Journal of Medical Genetics.

[16]  M. Baybis,et al.  Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. , 2003, Neurobiology of disease.

[17]  D. Kwiatkowski,et al.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. , 2001, American journal of human genetics.

[18]  J. Maynard,et al.  Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. , 1999, American journal of human genetics.

[19]  R. Snell,et al.  Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. , 1997, Human molecular genetics.

[20]  B. Scheithauer The Neuropathology of Tuberous Sclerosis , 1992, The Journal of dermatology.

[21]  J. Osborne,et al.  Epidemiology of Tuberous Sclerosis , 1991, Annals of the New York Academy of Sciences.